Marseille

• Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting
  2023-508798-94-00 5 2025-02-11 Heart failure
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No … Recruiting
  2023-509806-31-00 4 2025-02-11 Non-Small Cell Lung Cancer
• PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel … Recruiting
  2024-510772-20-00 4 2025-02-06 Rectal cancer locally advanced with microsatellite unstable or mismatc
• A Phase 2 Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM) Recruiting
  2024-513128-40-00 4 2025-02-06 Multifocal Motor Neuropathy
• Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting
  2024-511442-39-00 5 2025-02-05 Rheumatoid arthritis (RA)
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI … Recruiting
  2024-513475-41-00 5 2025-02-03 Multiple Sclerosis
• A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting
  2023-505320-54-00 4 2025-01-30 Multiple System Atrophy
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical alloge … Recruiting
  2023-506648-18-00 4 2025-01-14 haematological malignancies
• Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después … Recruiting
  2023-508741-40-00 10 2025-01-14 Non-small cell lung cancer
• SUPPRESS. Prophylactic frequent premature ventricular complexeS sUPPression on left ventriculaR function impairmEnt in aSymptomatic patientS Recruiting
  2024-516372-14-00 11 2025-01-13 Asymptomatic Patients with frequent PVCs and normal LVEF
• Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplas … Recruiting
  2023-506942-22-01 4 2025-01-10 paraneoplastic sensory neuropathy with anti-Hu antibodies
• A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad … Recruiting
  2023-509883-89-00 5 2025-01-09 Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
• Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non valvular atrial fibrillation: a randomized controll … Recruiting
  2023-507544-37-00 5 2025-01-08 patients with end-stage renal disease on chronic peritoneal dialysis a
• EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease … Recruiting
  2023-510507-21-00 10 2025-01-08 Intersitial lung disease related to systemic sclerosis
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting
  2023-506350-21-00 4 2025-01-06 Localized, resected, FIGO stage I (2018 classification), uterine leiom
• An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring Recruiting
  2024-515457-21-00 3 2024-12-30 Non-Hodgkin lymphoma and chronic lymphocytic leukemia
• BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ARVD.BRAVE Recruiting
  2023-505048-20-00 4 2024-12-20 Arrhythmogenic right ventricular dysplasia
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h … Recruiting
  2023-509717-36-00 5 2024-12-16 AF patients who have undergone successful PCI
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia

Showing 505–528 of 1,485 trials